The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism by Nechama  Morris et al.
The peptidyl-prolyl isomerase Pin1 determines
parathyroid hormone mRNA levels and stability
in rat models of secondary hyperparathyroidism
著者 Nechama  Morris, Uchida  Takafumi, Yosef-Levi 
Irit Mor, Silver  Justin, Naveh-Many  Tally
journal or
publication title








3102	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 119	 	 	 Number 10	 	 	 October 2009
The peptidyl-prolyl isomerase Pin1 
determines parathyroid hormone  
mRNA levels and stability in rat models  
of secondary hyperparathyroidism
Morris Nechama,1 Takafumi Uchida,2 Irit Mor Yosef-Levi,1 Justin Silver,1 and Tally Naveh-Many1
1Minerva Center for Calcium and Bone Metabolism, Nephrology Services, Hadassah Hebrew University Medical Center,  

















Parathyroid hormone (PTH) regulates serum calcium and phos-
phate levels and bone strength. In turn, PTH gene expression, 
PTH secretion, and parathyroid cell proliferation are determined 
by serum calcium and phosphate. Dietary calcium depletion and 
experimental chronic kidney disease (CKD) lead to secondary 
hyperparathyroidism characterized by increased PTH mRNA 
levels, serum PTH, and parathyroid cell proliferation (1). The 
changes in PTH mRNA levels due to calcium depletion as well 
as CKD are posttranscriptional, affecting mRNA stability (2, 3). 
They are mediated by the regulated binding of trans-acting fac-
tors to a 63-nt–long cis-acting AU-rich element (ARE) located in 
the PTH mRNA 3′ UTR (4, 5). A 26-nt element within the 63-nt 
sequence is the minimal protein-binding region and is conserved 
among species (4). A number of ARE-binding proteins have been 
identified. Among these, K-homology splicing regulator protein 
(KSRP) is an example of a decay-promoting factor that recruits 
the multiprotein 3′–5′ exoribonuclease complex, exosome (6), 
to target mRNAs (7). AU-rich binding factor 1 (AUF1) promotes 
either decay or stabilization, depending on the mRNA and cell 
type (8, 9). We have previously shown that AUF1 and KSRP have 
opposite effects on PTH mRNA stability. AUF1 binds to the 
PTH mRNA 63-nt ARE, increasing PTH mRNA t1/2 (10). KSRP 
interacts with the same 63-nt ARE element, but decreases PTH 
mRNA t1/2 (11). PTH mRNA interactions with AUF1 and KSRP 
are regulated by changes in serum calcium and phosphate con-
centrations and by CKD (11, 12).
The peptidyl-prolyl cis-trans isomerase Pin1 specifically binds 
phosphorylated Ser/Thr-Pro protein motifs and catalyzes the 
cis-trans isomerization of the peptide bonds, thereby changing the 
biological activity, phosphorylation, and turnover of its target 
proteins (13, 14). Pin1 consists of an aminoterminal protein-
protein interaction domain, the WW domain, which is involved 
in Pin1 binding to its Ser/Thr-Pro target phosphoproteins and 
a carboxyterminal peptidyl-prolyl cis-trans isomerase (PPIase) 
domain (15). Pin1 is the only mammalian enzyme known to spe-
cifically catalyze the cis-trans isomerization of Ser-Pro or Thr-Pro 
peptide bonds (16, 17). Pin1-catalyzed conformational regula-
tion has a profound impact on many key proteins involved in 
various cell functions (18, 19). Interestingly, Pin1 was recently 
shown to regulate the turnover of ARE-containing mRNAs, 
mainly cytokine mRNAs, through the interaction and isomeri-
zation of ARE-binding proteins. Pin1 interacts with AUF1 and 
thereby stabilizes both GM-CSF and TGF-β mRNAs (20, 21). In 
contrast to its degrading effect on these mRNAs, AUF1 is a PTH 
mRNA–stabilizing protein (10). We hypothesized that Pin1 may 
be involved in the regulation of PTH gene expression.
Here, we identify Pin1 as a PTH mRNA–regulating protein. We 
show that Pin1 activity is decreased in parathyroid extracts from 
calcium-depleted rats or in CKD rats, in which PTH mRNA levels 
and stability are increased. Accordingly, Pin1 inhibition by juglone 
increases serum PTH and PTH mRNA levels in the rat. This increase 
in PTH gene expression is posttranscriptional. In transfected cells, 
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overexpression of Pin1 decreases and Pin1 knockdown increases 
cotransfected PTH mRNA levels. These effects of Pin1 are dependent 
upon the PTH mRNA 3′ UTR ARE. Pin1 interacts with KSRP, and 
Pin1 overexpression leads to KSRP dephosphorylation, which deter-
mines KSRP-mediated PTH mRNA decay. In vivo, in the rat, Pin1 
inhibition prevents KSRP–PTH mRNA interaction. Finally, we show 
that Pin1–/– mice have increased serum PTH and PTH mRNA levels. 
Our results demonstrate a role for Pin1 in the regulation of PTH 
mRNA stability and in the response to calcium depletion and CKD.
Results
Pin1 activity is decreased in parathyroid extracts of rats with secondary 
hyperparathyroidism. We have previously reported that dietary cal-
cium depletion and experimental CKD lead to secondary hyper-
parathyroidism characterized by a posttranscriptional increase in 
PTH mRNA levels (22). To determine whether the prolyl isomerase 
Pin1 is involved in this regulation, we first showed Pin1 expression 
in parathyroid tissue by immunohistochemistry of rat parathyroid 
tissue (Figure 1A). We then analyzed Pin1 enzymatic activity in 
parathyroid extracts from control and secondary hyperparathy-
roidism rats. Rats were fed either a control diet or diets that were 
calcium restricted or supplemented with adenine and high phos-
phorus to induce CKD. Both diets increase serum PTH and PTH 
mRNA levels compared with a control diet fed to rats, with the 
effect of calcium depletion being greater than that of the adenine 
diet (11). At the end of the diet period, Pin1 activity was measured 
in microdissected parathyroid cytosolic lysates by an isomerase 
assay (23). PPIase activity was markedly reduced in parathyroid 
cytoplasmic lysates of both rats fed a calcium-restricted diet and 
CKD rats compared with parathyroid extracts from control rats 
(Figure 1, B and D). There was no change in Pin1 protein levels 
(Figure 1, C and E). These results indicate that Pin1 activity is 
decreased in response to changes in serum calcium and CKD. The 
decrease in Pin1 activity inversely correlates with the increased 
PTH mRNA levels and stability in these models.
Pin1 inhibition by juglone increases PTH mRNA in vivo. The decreased 
Pin1 activity in parathyroid extracts from secondary hyperparathy-
roidism rats suggests that Pin1 inhibition would lead to increased 
PTH mRNA levels. We therefore studied the effect of a specific and 
irreversible Pin1 inhibitor, juglone (23), on PTH gene expression in 
vivo. Juglone covalently inactivates Pin1 and accelerates its catab-
olism by the proteasome (20). Juglone was administered systemi-
cally by 2 daily i.p. injections. One hour after the second injection, 
there was the expected decrease in PPIase activity in the parathyroid 
cytoplasmic lysates (Figure 2A) and an increase in serum PTH levels 
(Figure 2B). To study the direct effect of Pin1 inhibition on PTH 
expression, we applied juglone topically on the parathyroid glands 
using a method that we have recently developed to study the effect 
of direct application of a compound to the parathyroid while main-
taining the glands in their physiological milieu (24). After 2 hours of 
juglone or vehicle administration, treated parathyroid glands were 
removed and analyzed for PPIase activity, Pin1 protein levels, and 
PTH mRNA levels. Pin1 protein levels and PPIase activity were mark-
edly decreased in the juglone-treated parathyroid cytoplasmic lysates 
(Figure 2, C and D). Importantly, juglone administration markedly 
increased PTH mRNA levels by both Northern blots and real-time 
quantitative RT-PCR (qRT-PCR) (Figure 2, E and F). Therefore, Pin1 
inhibition by juglone increases PTH gene expression in vivo.
Pin1 inhibition increases PTH mRNA levels by a posttranscriptional 
mechanism. To study the mechanism of the effect of Pin1 inhibition 
by juglone on PTH gene expression, we performed nuclear run-on 
assays with isolated nuclei from parathyroid glands of rats treated 
topically with juglone or control rats, as above (Figure 2, C–F). PTH 
transcription was the same in treated and nontreated parathyroid 
Figure 1
PPIase activity is decreased in parathyroid extracts from rat with secondary hyperparathyroidism due to a calcium-depleted diet or an adenine 
and high-phosphorus diet. (A) Immunohistochemistry using an anti-Pin1 antibody or IgG showing specific expression of Pin1 in the parathyroid 
cells and not in interstitial tissue or blood vessels. Original magnification, ×200. (B and D) Pin1 isomerase assays. PPIase activity of parathyroid 
cytoplasmic lysates from a pool of 5 rats fed a calcium-depleted diet (B) or an adenine and high-phosphorus diet (D) compared with parathyroid 
extracts from control rats. The results are representative of 3 independent experiments and are presented as mean ± SEM of 3 measurements 
from 1 of the experiments (B) and as mean ± SEM of 3 measurements from the 3 experiments combined (D). The decrease in Pin1 activity in B 
and D was significant (P < 0.05) compared with the respective controls at all the time intervals studied. Control: low Ca or adenine, P < 0.05 at 
all time intervals. (C and E) Immunoblot analysis using anti-Pin1 or anti-GAPDH antibodies for parathyroid extracts, as in B and D.
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glands, indicating that the increase in PTH mRNA after Pin1 inhi-
bition by juglone is posttranscriptional (Figure 2, G and H). To 
further demonstrate the posttranscriptional effect of juglone on 
PTH gene expression, we performed RNase protection assays using 
antisense probes for the PTH mRNA 3′ UTR (exon) or for the first 
intron of PTH mRNA as a marker of newly transcribed pre–PTH 
mRNA. As shown in Figure 2I, juglone-treated parathyroid glands 
had higher levels of PTH mRNA compared with control parathy-
roids based on the RNase protection assay using the PTH mRNA 3′ 
UTR probe, similar to the results obtained by Northern blots and 
qRT-PCR (Figure 2, E and F). A probe for GAPDH mRNA 3′ UTR 
was used as a control that was not affected by juglone (Figure 2I). 
In contrast, there was no difference in the pre-mRNA levels for the 
PTH transcript in juglone-treated parathyroid glands compared 
with controls, as indicated using the probe for the first intron 
(Figure 2I). Together, these results indicate that the increased PTH 
mRNA levels after Pin1 inhibition by juglone is posttranscription-
al, similar to the regulation of PTH gene expression in secondary 
hyperparathyroidism in which Pin activity is decreased (Figure 
1, B and D). Thus, the physiological function of Pin1 may be to 
decrease PTH gene expression posttranscriptionally.
Pin1 regulates PTH mRNA stability in cotransfected HEK293 cells, and 
this is mediated by the PTH mRNA 3′ UTR ARE. Since a parathyroid 
cell line is not available, the direct effect of Pin1 on PTH mRNA 
levels was studied in transiently transfected HEK293 cells. Pin1 
overexpression decreased PTH mRNA levels with no effect on 
endogenous L32 or control cotransfected growth hormone (GH) 
mRNA levels (Figure 3, A–C). The effect of Pin1 overexpression on 
Figure 2
Pin1 inhibition by juglone increases PTH mRNA in vivo posttranscriptionally. (A and B) Juglone i.p. (A) PPIase activity assays of parathyroid cyto-
plasmic lysates from rats injected i.p. with juglone or vehicle. (B) Serum PTH in rats as in A. (C–F) Juglone applied topically. (C) PPIase activity 
of parathyroid cytoplasmic lysates from rats treated with juglone or vehicle applied topically; data in A and C are presented as mean ± SEM 
(n = 3) from 1 of 3 repeat experiments; P < 0.05 at 5–30 seconds. (D) Immunoblots of the extracts in C for Pin1 and GAPDH. (E) Northern blots of 
PTH mRNA levels after juglone, in rats as in C. The lanes were run on the same gel but were noncontiguous (white line). (F) qRT-PCR analysis 
for PTH mRNA in rat parathyroids as in C; *P < 0.05. (G) Nuclear run-ons of PTH transcription in isolated nuclei of parathyroids from 5 rats in 
each group after topical juglone (J) or vehicle (C). (H) Quantification of PTH mRNA transcription in G, showing no difference in PTH transcrip-
tion. The same result was obtained in a repeat experiment. (I) RNase protection analysis (RPA) of total parathyroid RNA from rats after topical 
juglone or vehicle. Left panels: RPA using an antisense probe for the PTH mRNA 3′ UTR or for control GAPDH mRNA. Right panel: RPA using 
an antisense probe for the first intron (newly transcribed pre–PTH mRNA). The intact probes before and after RNase treatment (arrows to the 
left and right of the gels, respectively) and hybridization with tRNA as a nonspecific control are shown. Juglone increased PTH mRNA but not 
the pre–PTH mRNA or GAPDH mRNA.
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Figure 3
Pin1 regulates PTH mRNA steady-state levels and stability in transfected cells. (A–F) Pin1 overexpression. HEK293 cells were transiently 
cotransfected with expression plasmids for human PTH or GH and for GFP-Pin1 or control pcDNA3 plasmids. (A) Immunoblots of protein 
extracts at 48 hours for Pin1 and α-tubulin. (B) Northern blots for PTH mRNA. (C) Northern blots for GH mRNA. (D) IVDA for polyadenylated 
full-length rat PTH mRNA (top) or polyadenylated PTH mRNA without the ARE (bottom) and extracts from cells transfected with GFP-Pin1 or 
control plasmids. (E) Quantification of the IVDAs in D and 2 additional IVDAs; mean ± SEM of intact transcript; *P < 0.05. (F and G) Cells were 
transiently cotransfected with expression plasmids for PTH and GFP-Pin1 or Pin1 mutants at the WW domain (W34A) or at the PPIase domain 
(K63A,R68/69A). (F) Northern blots for PTH mRNA. (G) Quantification of 3 Northern blots; mean ± SEM; *P < 0.05. (H–L) Pin1 knockdown. Cells 
were cotransfected with a human PTH plasmid and either Pin1 or control CAT siRNAs. (H) Immunoblots of Pin1 and α-tubulin after transfec-
tion. (I) Northern blots for PTH mRNA. (J) Quantification by qRT-PCR analysis for PTH mRNA after Pin1 siRNA. (K) IVDA for full-length rat PTH 
mRNA (top) or rat PTH mRNA without the ARE (bottom) and extracts from cells with either CAT or Pin1 siRNAs. (L) Quantification of 3 IVDAs; 
mean ± SEM of intact transcript at time 0; *P < 0.05.
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PTH mRNA stability was measured by in vitro degradation assays 
(IVDAs) using transfected cell extracts and polyadenylated full-
length radio-labeled PTH mRNA transcripts (11). Extracts from 
Pin1-overexpressing cells led to accelerated PTH mRNA decay in 
vitro compared with extracts from control transfected cell extracts 
(Figure 3, D and E). The t1/2 of PTH mRNA decreases from more 
than 100 minutes with the control transfected extracts to 50 min-
utes by the Pin1-overexpressing extracts. Pin1 overexpression, 
however, had no effect on the in vitro decay of a truncated poly-
adenylated PTH mRNA transcript lacking the PTH mRNA 3′ UTR 
ARE (Figure 3, D and E), suggesting an ARE-dependent effect of 
Pin1 to increase PTH mRNA decay.
Both the binding (WW) and isomerase (PPIase) activities of Pin1 
are normally required for Pin1 to regulate the function of its sub-
strates (16, 25). To determine whether one or both of these activi-
ties are required for the decrease in PTH mRNA levels by Pin1, we 
cotransfected the PTH expression plasmid with expression plasmids 
for mutated Pin1 at either the binding domain (W34A) or the PPIase 
domain (R68/69A, K63A) (19). Pin1 overexpression decreased PTH 
mRNA levels as before (Figure 3B), as did the K63A mutant (Figure 
3, F and G). However, mutants for both the binding domain (W34A) 
and another PPIase domain (R68/69A) attenuated the downregula-
tion of PTH mRNA induced by WT Pin1 (Figure 3, F and G). There-
fore, Pin1 overexpression decreases PTH mRNA levels, and both the 
WW and PPIase domains are necessary for this effect.
Next, we decreased Pin1 protein levels using siRNAs and assessed 
the resulting effects on cotransfected PTH mRNA levels. A 75% 
reduction in Pin1 protein levels (Figure 3H) led to a 3-fold increase 
in PTH mRNA levels by both Northern blot and qRT-PCR (Figure 
3, I and J). Similarly, PTH mRNA t1/2 was prolonged in IVDAs with 
extracts from Pin1-depleted cells compared with extracts from cells 
transfected with a control bacterial chloramphenicol acetyltrans-
ferase (CAT) siRNA (Figure 3, K and L). The t1/2 of PTH mRNA 
increased from 50 minutes by control extracts to more than 100 
minutes by the Pin1 knockdown extracts. As with Pin1 overexpres-
sion (Figure 3, D and E), the t1/2 of a PTH transcript lacking the 3′ 
UTR ARE was not affected by Pin1 depletion (Figure 3, K and L). 
Together, the Pin1 knockdown and overexpression experiments 
indicate that Pin1 specifically decreases steady-state PTH mRNA 
levels and PTH mRNA stability by IVDA and this is dependent 
upon the PTH mRNA ARE.
To determine whether the regulation of PTH mRNA levels by 
Pin1 is mediated by the PTH mRNA ARE in the transfected cells, 
we used a GH reporter gene containing the rat PTH 63-nt ARE 
within its 3′ UTR (GH63) (Figure 4A) (11). As in our previous 
reports, the PTH mRNA ARE decreased GH63 mRNA levels com-
pared with WT GH mRNA (Figure 4B) (4). Pin1 overexpression led 
to a further decrease in chimeric GH63 mRNA levels but had no 
effect on WT GH mRNA levels (Figure 4, B and C). We then stud-
ied the effect of the Pin1 inhibitor juglone on GH63 or WT GH. 
Juglone decreased endogenous Pin1 protein levels in HEK293 cells, 
as expected (Figure 4D). Importantly, juglone increased GH63 
mRNA levels compared with control cells treated with vehicle but 
had no effect on WT GH mRNA levels (Figure 4, E and F). Togeth-
er, our results indicate that Pin1 decreases steady-state PTH mRNA 
levels, through the PTH mRNA ARE.
Figure 4
Pin1 regulates PTH mRNA levels through the PTH mRNA ARE. (A) Schematic representation of mRNAs for PTH, GH, and chimeric reporter GH 
containing the PTH mRNA ARE (GH63) used for transfections. (B and C) Pin1 overexpression. HEK293 cells were transiently cotransfected with 
expression plasmids for either GH or a chimeric GH63 (GH63) and GFP-Pin1 or pcDNA3 (control). (B) Northern blot analysis for PTH mRNA. (C) 
Quantification of 2 Northern blots as in B for GH (left) and GH63 (right); mean ± SEM; *P < 0.05 compared with GH63 without Pin1. (D–F) Effect 
of juglone on GH63. Cells were transiently transfected with expression plasmids for either GH or GH63 and incubated with juglone or vehicle 
(–). (D) Immunoblots for Pin1 in cell extracts after juglone or vehicle. (E) Northern blots for GH mRNA. (F) Quantification of Northern blots of 3 
independent experiments as in E (*P < 0.05). The lanes in B and E were run on the same gel but were noncontiguous (white lines).
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Pin1 interacts with the PTH mRNA decay–promoting protein KSRP, 
and the effects of KSRP and Pin1 on PTH mRNA are interdependent. 
PTH mRNA stability is regulated by the coordinated interaction 
of AUF1 and KSRP with the same PTH mRNA 3′ UTR 63-nt ARE 
(11). AUF1 interacts with Pin1, resulting in AUF1 isomerization 
and hyperphosphorylation upon Pin1 activation (20). KSRP-Pin1 
interaction has not been reported. To study such interaction, we 
performed coimmunoprecipitation analysis of FLAG-KSRP–trans-
fected HEK293 cell extracts. Endogenous Pin1 was specifically 
immunoprecipitated by FLAG-KSRP (Figure 5A). Similarly, Pin1 
immunoprecipitated FLAG-KSRP in these extracts (Figure 5A).
To determine the functional importance of KSRP-Pin1 interac-
tion, we studied the effect of Pin1 inhibition by juglone on the 
KSRP-mediated regulation of PTH gene expression in transfected 
cells. For that, HEK293 cells were transiently cotransfected with 
expression plasmids for the GH63 reporter gene or WT GH and 
either a control or KSRP expression plasmid. KSRP decreased 
GH63-nt mRNA levels while having no effect on WT GH mRNA 
(Figure 5, B and C), as in our previous studies (11). Pin1 inhibition 
by juglone specifically prevented the KSRP-mediated decrease in 
GH63 mRNA levels and restored GH63-nt mRNA levels to those 
of control cells. There was no effect of either KSRP or juglone on 
WT GH mRNA levels (Figure 5, B and C).
We then studied the effect of KSRP depletion by siRNA on the 
regulation of GH63 mRNA levels by Pin1 overexpression. HEK293 
cells were cotransfected with GH or GH63-nt and either a control 
Figure 5
Pin1 interacts with the PTH mRNA decay–promoting protein KSRP, and the effects of Pin1 and KSRP on the PTH mRNA ARE are interde-
pendent. (A) Pin1-KSRP interaction. HEK293 cells were transiently transfected with FLAG-KSRP plasmid and extracts immunoprecipitated 
with anti-FLAG or anti-Pin1 antibodies or IgG, run on SDS PAGE, and immunoblotted with the corresponding antibodies. (B and C) Cells were 
cotransfected with either GH or GH63 and KSRP or control pcDNA3 plasmids. After 48 hours, increasing concentrations of juglone were added 
for an additional 4 hours. (B) Northern blots for GH mRNA. (C) Quantification of 3 Northern blots as in B; *P < 0.05 compared with GH mRNA 
without KSRP; **P < 0.05 compared with GH63 mRNA without KSRP. (D–F) KSRP knockdown. Cells were cotransfected with either GH or 
GH63 and GFP-Pin1 or control pcDNA3 plasmids together with either CAT or KSRP siRNAs. (D) Immunoblots for KSRP and α-tubulin protein 
levels 48 hours after transfection, showing decreased KSRP in KSRP siRNA–transfected cells. Densitometry analysis of KSRP corrected for 
α-tubulin is shown below the gels. (E) Northern blots for GH mRNAs. The lanes were run on the same gel but were noncontiguous (white line). 
(F) Quantification of 3 Northern blots as in E for GH (left) and GH63 (right); *P < 0.05. Data in C and F are represented as mean ± SEM.
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or a Pin1 expression plasmid (Figure 5, D–F). Pin1 overexpression 
decreased GH63-nt mRNA levels while having no effect on the 
control GH mRNA as before (Figure 5, E and F, and Figure 4, B and 
C). siRNA-mediated knockdown of KSRP by approximately 50% 
(Figure 5D) caused a specific 3-fold increase in GH63-nt mRNA 
levels compared with control siRNAs (not shown) as before (11). 
Importantly, the effect of Pin1 in decreasing GH63 mRNA levels 
was attenuated in the KSRP-depleted HEK293 cells (Figure 5, E 
and F). Together, these results indicate that Pin1 and KSRP act 
together to regulate PTH mRNA levels.
KSRP is phosphorylated at S181, and Pin1 overexpression induces dephos-
phorylation of KSRP at serine residues. KSRP is a phosphoprotein with 2 
reported phosphorylation sites, at S193 and T692 (26). To identify 
a Pin1 interaction consensus site on KSRP, we transfected HEK293 
cells with FLAG-KSRP and analyzed immunoprecipitated KSRP by 
mass spectrometry. This analysis identified a new phosphorylation 
site at S181 in the KVQI*SPDSGGLPER peptide that has not been 
previously reported (Figure 6A and Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI39522DS1). This serine residue is adjacent to proline, making 
it a putative Pin1-interacting site. To study the role of S181 on 
KSRP-Pin1 interaction, we cotransfected HEK293 cells with expres-
sion plasmids for Pin1 and either FLAG-KSRP or the FLAG-KSRP 
S181A mutant. Cotransfected Pin1 did not immunoprecipitate 
FLAG-KSRP S181A but did precipitate FLAG-KSRP (Figure 6B 
and Figure 5A). In contrast, both KSRP S193A and T692A mutants 
bound Pin1 as the WT KSRP (Supplemental Figure 2, A and B).
We then studied the effect of Pin1 overexpression on KSRP 
phosphorylation. HEK293 cells were transfected with FLAG-
KSRP and a Pin1 expression plasmid. Immunoprecipitated 
FLAG-KSRP was analyzed by immunoblots with anti–phospho-
serine antibody. Pin1 overexpression decreased the amount of 
phosphorylated KSRP at serine residues (Figure 6C). Therefore, 
Pin1 decreases KSRP phosphorylation at serine residues, and an 
intact serine at amino acid 181 but not at 193 is necessary for 
Pin1-KSRP interaction in transfected cells.
S181A KSRP mutant is more potent than WT KSRP in decreasing PTH 
mRNA levels in transfected cells. KSRP phosphorylation at S193 by 
AKT prevents the binding of KSRP to the exosome complex and 
thereby KSRP-induced mRNA decay (27). We studied the effect of 
the newly identified S181 phosphorylation site on KSRP-mediated 
PTH mRNA degradation. HEK293 cells were cotransfected with 
expression plasmids for PTH and either WT or S181A KSRP. Both 
WT and S181A KSRP were expressed at the same levels (Figure 
6D). WT KSRP overexpression decreased PTH mRNA levels (Fig-
ure 6, E and F) as before (26). The overexpressed S181A mutant 
was more potent than WT KSRP (Figure 6, E and F). These results 
were confirmed by IVDAs using extracts from HEK293 cells trans-
fected with either KSRP or KSRP S181A mutant and uniformly 
labeled PTH mRNA as above. As expected, overexpression of KSRP 
specifically decreased PTH mRNA stability compared with control 
extracts (Figure 6, G and H). PTH mRNA decay was further acceler-
ated by cell extracts overexpressing KSRP S181A compared with 
extracts expressing WT KSRP (Figure 6, G and H). There was no 
difference in mRNA decay of the truncated PTH transcript lacking 
the PTH mRNA ARE (Figure 6, G and H). These results demon-
strate that dephosphorylated KSRP at the Pin1 interaction site, 
S181, is more potent than WT KSRP in decreasing PTH mRNA 
levels and stability. They suggest that Pin1 acts through dephos-
phorylation of KSRP to decrease PTH mRNA levels in an ARE-
dependent manner in transfected cells.
We therefore hypothesized that S181A KSRP, which does not 
bind Pin1, would not be influenced by Pin1 inhibition. HEK293 
cells were transiently cotransfected with expression plasmids for 
PTH and either WT or S181A KSRP and were incubated with 
juglone, as above (Figure 4, E and F). KSRP overexpression caused 
a 90% reduction in PTH mRNA levels (Figure 6I). Juglone treat-
ment prevented this decrease dose dependently (Figure 6I), simi-
lar to its effect on reporter GH63 (Figure 4, E and F). In contrast, 
juglone had no effect on PTH mRNA levels at 3 and 5 μM in cells 
expressing S181A KSRP and only an effect at the highest juglone 
concentration (Figure 6I). Together, these results indicate that 
Pin1–KSRP interaction is dependent upon S181 KSRP phosphory-
lation, suggesting that Pin1 leads to dephosphorylation at this site 
and thereby activation of KSRP.
Pin1 interacts with KSRP and regulates KSRP–PTH mRNA interac-
tion in parathyroid glands. In vivo in the parathyroid, Pin1 activity 
was decreased in parathyroid extracts of rats with increased PTH 
mRNA levels and stability (Figure 1), and Pin1 inhibition by 
juglone increased PTH mRNA levels posttranscriptionally (Figure 
2). We have previously shown that posttranscriptional regulation 
of PTH gene expression is mediated by differential binding of 
KSRP to the PTH mRNA ARE (11). To study KSRP–PTH mRNA–
Pin1 interactions in vivo, we first showed KSRP-Pin1 interaction 
in rat parathyroid gland extracts (Figure 7A). KSRP was coimmu-
noprecipitated by Pin1 (Figure 7A), indicating that these proteins 
interact also in the parathyroid, similar to their interaction in 
HEK293 cells (Figure 5A).
We then asked whether the effect of juglone to increase PTH 
mRNA levels is mediated by an effect of Pin1 on KSRP–PTH mRNA 
interaction in vivo. Juglone was applied topically to rat parathy-
roid glands as above (Figure 2, C–F). The parathyroid glands were 
then cross-linked and analyzed by RNA immunoprecipitation 
Figure 6
Identification of KSRP phosphorylation at S181 and its role in KSRP-
Pin1 interaction and PTH mRNA regulation. (A) Mass spectrometry. 
MS spectra of tryptic mixture of immunoprecipitated FLAG-KSRP 
from transfected cells. The peak at 677.8555 m/z was assigned as the 
unphosphorylated form of amino acids 177–197 (left), and the peak at 
717.8390 m/z the phosphorylated form of the peptide (right). Asterisk 
indicates serine phosphorylation. The P probability of the assignment 
was equal to 7.51E-06. Sequest X score was equal to 3.25. (B) KSRP-
Pin1 interaction. HEK293 cells were cotransfected with either FLAG-
KSRP or FLAG-KSRP S181A and GFP-Pin1 or control plasmid. Extracts 
were immunoprecipitated with either anti-Pin1 or IgG. The pellets and 
input were immunoblotted as indicated. (C) KSRP dephosphorylation. 
Cells were cotransfected with FLAG-KSRP and GFP-Pin1 or control 
plasmid. Extracts were immunoprecipitated with anti-FLAG or IgG and 
immunoblotted with anti–phosphor-serine or anti-FLAG antibody. (D–H) 
Cells were cotransfected with the PTH plasmid or control and either 
FLAG-KSRP or FLAG-KSRP S181A. (D) Immunoblots showing equal 
amounts of KSRP. (E) Northern blots of PTH mRNA. The lanes were run 
on the same gel but were noncontiguous (white line). (F) qRT-PCR for 
PTH mRNA as in E. *Compared with control; **compared with KSRP. 
(G) IVDA using cell extracts and full-length human PTH mRNA (top) 
or PTH mRNA without the ARE (bottom). (H) Quantification of IVDA 
results in 3 experiments; mean ± SEM of time 0; KSRP compared with 
both control and S181A; *P < 0.05. (I) Cells were cotransfected with the 
PTH and KSRP or S181A plasmids with and without juglone. RNA was 
analyzed by qRT-PCR for PTH mRNA; *P < 0.05 (n = 3) compared with 
cells expressing KSRP and not treated with juglone.
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(RIP) using anti-KSRP antibody and qRT-PCR analysis. As shown 
in Figure 7B, RIP analysis showed a specific interaction of KSRP 
with PTH mRNA and not with a control HPRT mRNA, as we have 
previously published (11). Juglone increased PTH mRNA levels 
in the input fraction (Figure 7C) as above (Figure 2, E and F). 
Pin1 inhibition led to a marked decrease in the amount of KSRP-
bound PTH mRNA compared with vehicle-treated parathyroid 
glands (Figure 7D). This decrease in KSRP–PTH mRNA interac-
tion was not a result of changes in KSRP protein levels that were 
unchanged by juglone treatment (Figure 7E). Juglone led to the 
expected decrease in Pin1 protein levels (Figure 7E) (23). AUF1 pro-
tein levels were also dramatically decreased in the juglone-treated 
parathyroid glands, as reported by Shen et al. (20, 21). Due to the 
marked decrease in AUF1 protein levels here, it was not possible to 
study AUF1–PTH mRNA interactions in the juglone-treated para-
thyroids. Our results indicate that Pin1 inhibition by juglone in 
vivo decreases KSRP–PTH mRNA interaction in the parathyroid. 
This may contribute to the increased PTH mRNA levels induced by 
juglone (Figure 7C and Figure 2, E and F).
Pin–/– mice have increased PTH expression. Our results indicate a cor-
relation between Pin1 activity and PTH mRNA levels in vivo and 
regulation of PTH gene expression by Pin1 in vitro. To study the 
role of Pin1 in PTH gene expression in vivo more directly, we mea-
sured serum PTH, calcium, and phosphorus levels in mice with 
genetic deletion of Pin1 (Pin–/– mice) (28). Serum PTH levels in 
the Pin1–/– mice were 3-fold higher than in WT littermates (Figure 
8A). There was no change in serum calcium and phosphorus lev-
els (Figure 8, B and C) nor in CYP27B1 
(1α-hydroxylase) mRNA levels (Sup-
plemental Figure 3). Therefore, the 
increased serum PTH was not secondary 
to changes in serum calcium or phospho-
rus levels. Immunohistochemistry using 
an anti-PTH antibody demonstrated a 
2-fold increase in PTH protein content 
in the parathyroid gland of the Pin–/– 
mice compared with control WT litter-
mates (Figure 8, D and E), in agreement 
with the high–serum PTH levels in the 
Pin1–/– mice. Similarly, in situ hybrid-
ization demonstrated an approximately 
2-fold increase in PTH mRNA levels in 
the parathyroid gland of the Pin–/– mice 
(Figure 8, F and G). Together, these 
results indicate that Pin1 determines 
basal PTH levels in vivo.
Discussion
The increased PTH mRNA levels of 
secondary hyperparathyroidism due to 
calcium depletion or CKD is mediated 
by the interaction of trans-acting RNA-
binding proteins with a defined cis-act-
ing ARE in the PTH mRNA 3′ UTR. 
AUF1 and Unr (upstream of N-ras) sta-
bilize and KSRP destabilizes the PTH 
mRNA (11, 22). Many RNA-binding 
proteins, including KSRP and AUF1, 
are phosphoproteins, and their activity 
is tightly regulated through phosphor-
ylation and dephosphorylation signaling cascades. In particular, 
AUF1 is posttranslationally modified in the parathyroid in correla-
tion with PTH gene expression in secondary hyperparathyroidism 
(29). Here, we demonstrate for what we believe is the first time that 
Pin1 is a critical mediator of PTH expression in vivo and in vitro in 
transfected cells. Pin1–/– mice have increased levels of serum PTH, 
parathyroid PTH protein, and PTH mRNA levels, indicating that 
Pin1 determines basal PTH expression in vivo. Moreover, Pin1 
isomerase activity is decreased in parathyroid extracts of rats fed a 
calcium-depleted diet or CKD rats in which PTH mRNA levels and 
stability are increased. Juglone inhibits Pin1 activity and leads to 
its degradation by the proteasome (20). Juglone has also recently 
been shown to inhibit postmitotic dephosphorylation and the 
exit of mitosis independently of Pin1 by covalent modification of 
sulfhydryl groups in proteins essential for metaphase/anaphase 
transition (30). We show that Pin inhibition by juglone increas-
es PTH mRNA levels in vivo posttranscriptionally. The effect of 
juglone occurs when it is applied topically on the parathyroid or 
given systemically, indicating a direct effect of the Pin1 inhibitor 
on the parathyroid. We used HEK293 cells, which reproduce cer-
tain aspects of the regulation of a transfected PTH gene, to study 
the effect of Pin1 on PTH gene expression (11, 31, 32). Pin1 regu-
lates PTH gene expression in transiently transfected HEK293 cells, 
and this regulation is dependent upon the PTH mRNA 3′ UTR 
ARE and KSRP. We identify KSRP as a new target protein for Pin1. 
Pin1 interacts with KSRP and leads to KSRP dephosphorylation, 
which enhances the KSRP-mediated decrease in PTH mRNA levels. 
Figure 7
Pin1 interacts with KSRP and regulates KSRP–PTH mRNA interaction in parathyroid glands. (A) 
Pin1-KSRP interaction in the parathyroid. Pin1 was immunoprecipitated from microdissected para-
thyroid extracts using anti-Pin1 antibody or IgG, fractionated on SDS PAGE, and analyzed by 
immunoblots for KSRP and Pin1. The lanes were run on the same gel but were noncontiguous 
(white line). (B–D) RIP analysis. Parathyroid glands were subjected to juglone or vehicle applied 
topically. RIP was performed on rat parathyroid glands using either anti-KSRP or control IgG. 
RNA from total lysate (input) and KSRP (IP-KSRP) or control IgG–bound fractions was assayed 
by qRT-PCR for PTH and control HPRT mRNAs. (B) Agarose gel of qRT-PCR products for PTH 
and HPRT. The size of PCR products was consistent with the predicted lengths of the amplified 
fragments. (C) PTH mRNA levels in the input. (D) mRNA levels in immunoprecipitated samples, 
corrected for mRNA levels in input; mean ± SEM of 3 experiments using parathyroids from pools 
of different rats. (E) Immunoblots of the parathyroid extracts as in C (input). *P < 0.05.
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In vivo, Pin1 inhibition decreases KSRP–PTH mRNA interaction, 
which would lead to the increased PTH mRNA and serum PTH 
levels after juglone administration.
The Pin1–/– mice have high serum PTH and PTH mRNA levels 
without the expected hypercalcemia or hypophosphatemia or 
increase in CYP27B1 (1α-hydroxylase) mRNA levels. This may 
represent downregulation of the PTH receptor in these knockout 
mice. In fact, the bones of Pin1–/– mice are markedly abnormal, 
which was attributed to a premature aging phenotype and not 
hyperparathyroidism (33).
It was recently shown in HeLa cells that Pin1 shuttles between 
nuclear and cytoplasmic domains. A nuclear localization signal 
located at the PPIase domain is based on 3 residues: Lys63, Arg68, 
and Arg69 (34). Interestingly, our results indicate that even though 
mutation at Lys63 did not affect Pin1 activity, double-point muta-
tion at Arg68 and Arg69 residues dramatically disrupted Pin1 activ-
ity on PTH mRNA levels. The effect of the R68/69 mutation on 
Pin1 activity here may be due to damage to the Pin1 PPIase domain 
itself by the mutation. The WW-binding domain mutation (W34A) 
functions as a dominant negative mutation by preventing endog-
enous Pin1 from binding to Ser/Thr-Pro targets (35). Mutation at 
the WW domain attenuated the decrease in PTH mRNA levels by 
Pin1. Together, our results suggest that both the Pin1 PPIase and 
WW domains are necessary for its effect on PTH mRNA levels.
AUF1 was shown to be a Pin1 target protein (20, 21). AUF1 con-
sists of 4 isoforms: p37, p40, p42, and p45 (36). Pin1 inhibition by 
juglone in eosinophil cells leads to proteosome-mediated degrada-
tion of 3 of the 4 AUF1 isoforms, p40, p42, and p45, while isoform 
p37 remains stable and destabilizes TGF-β and GM-CSF mRNA (20, 
21). The stabilizing action of AUF1 on the PTH mRNA is in con-
trast to its effect on many other ARE-containing mRNAs in which 
it is a destabilizing factor (10, 37). In the parathyroid, juglone led to 
degradation of all 4 AUF1 isoforms to undetectable levels (Figure 
7E). We could therefore not determine a contribution of any of the 
AUF1 isoforms to the effect of Pin1 on PTH gene expression. It is 
paradoxical that juglone increased PTH mRNA levels both in trans-
fected cells and in the parathyroid while decreasing protein levels of 
AUF1, which is a PTH mRNA–stabilizing protein. It is possible that 
small amounts of AUF1 that remain bind with a higher affinity to 
the PTH mRNA 3′ UTR and stabilize the PTH mRNA.
We show that the effect of KSRP in decreasing PTH gene expres-
sion is dependent upon Pin1. Moreover, Pin1 inhibition by juglone 
prevents KSRP-mediated PTH mRNA decay through the PTH 
mRNA ARE and decreases KSRP–PTH mRNA interaction in vivo 
with no change in KSRP protein levels. KSRP is a phosphoprotein 
with 2 characterized phosphorylation sites, S193 and T692 (26, 27). 
T692 is adjacent to a proline, making it a putative consensus Pin1-
interacting site. Mutations at these 2 sites did not interfere with 
Figure 8
Pin–/– mice have high serum PTH and PTH mRNA levels. (A–C) Serum PTH, calcium, and phosphate levels in WT (n = 18) and Pin1–/– (n = 14) 
mice. (D) Immunostaining of thyroparathyroid section for PTH. (E) Quantification of data presented in 6 sections from each group. (F) In situ 
hybridization for PTH mRNA in thyroparathyroid sections. (G) Quantification of the in situ hybridization staining in 6 sections from each group. 
Original magnification, ×100 (D and F). *P < 0.05. PT, parathyroid; T, thyroid tissue.
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KSRP-Pin1 interaction, indicating that these 2 phosphorylated 
sites are not the Pin1-interacting sites. We identify a new phos-
phorylation site at S181 in the N terminus of the protein. S181 
is adjacent to proline, forming a potential Pin1 interaction site. 
Indeed, the S181A mutation prevented Pin1-KSRP interaction and 
enhanced PTH mRNA destabilization by KSRP compared with 
WT KSRP. Moreover, Pin1 inhibition by juglone did not affect the 
decrease in PTH mRNA levels by KSRP S181A.
Our results suggest that phosphorylated KSRP at S181 is inac-
tive. Upon interaction with Pin1, cis-trans isomerization of the 
proline bond in KSRP leads to conformational change, exposing 
the phosphorylated S181 residue and possibly additional phos-
phorylation sites. This leads to dephosphorylation, thus activat-
ing KSRP, which then interacts with PTH mRNA and enhances 
its decay (Figure 9). A low calcium diet and CKD led to decreased 
Pin1 isomerase activity in the parathyroids of these rats. This 
decreased Pin1 activity would prevent KSRP dephosphorylation, 
resulting in decreased KSRP–PTH mRNA interaction, inhibition 
of PTH mRNA degradation, and increased PTH mRNA levels. Con-
sistent with this finding, Pin1 inhibition by juglone increases PTH 
mRNA levels and decreases KSRP–PTH mRNA interaction. Pin1 
is therefore a regulator of PTH gene expression. Pin1 determines 
basal PTH levels and the response of the parathyroid to chronic 
hypocalcemia and CKD.
Methods
Animals. Weanling male Sabra rats were fed either control or calcium-
depleted diets (Teklad) for 2 weeks (2). Calcium depletion results in hypo-
calcemia (controls, 10.5 ± 0.4; low calcium, 4.8 ± 0.5 mg/dl; n = 10) and 
increased serum PTH (controls, 56 ± 12; low calcium, 632 ± 57 pg/ml). 
Adult male rats (100–120 g) were fed a control diet or a 0.75% adenine, 
high-phosphorus (3.0%) diet for 7 days to induce renal failure (CKD). At 
7 days, there was an increase in serum creatinine (controls, 0.27 ± 0.03 μM; 
adenine, 0.7 ± 0.08 μM; n = 10), no change in serum phosphate (controls, 
10.9 ± 0.25; adenine, 9.9 ± 0.3 mg/dl), and increase in serum PTH (con-
trols, 66 ± 22 pg/ml; adenine, 338 ± 113). Serum biochemistry for calcium, 
phosphorus, and creatinine were measured using a QuantiChrom Calcium 
Phosphate Assay Kit (BioAssay Systems). Serum rat intact PTH levels were 
measured using the intact PTH ELISA Kits (Immunotopics).
For systemic juglone admission, rats were injected i.p. with juglone (1 g/1 kg/d) 
or a vehicle (ethanol) for 2 days, and rats were sacrificed 1 hour after the sec-
ond injection. For topical juglone administration, the parathyroid glands of 
anesthetized rats were exposed and submerged in DMEM containing either 
5 μM juglone or vehicle (ethanol, diluted 1:104) for 2 hours. All animal exper-
iments were approved by the Institutional Animal Care and Use Committees 
of the Hadassah Hebrew University and Tohoku University.
Pin1 activity assay. Pin1 assay was performed as described (23). Micro-
dissected parathyroid glands (pool of 5) were placed on ice in a reaction 
buffer containing 100 mM NaCl, 50 mM HEPES, pH 7, 2 mM DTT, and 
0.04 mg/ml BSA. The glands were homogenized using a mini-bead beat-
er (Biospec Products) and the supernatant cleared by centrifugation at 
12,000 g for 10 minutes (4°C). PPIase activity was measured using equal 
amounts of parathyroid cytoplasmic lysates and α-chymotrypsin using 
a synthetic tetrapeptide substrate Suc-Ala-Glu-Pro-Phe-pNa (Peptides 
International). Absorption at 390 nM was measured using an Ultro-
spec 2000 spectrophotometer. The results are expressed as the mean of 
3 measurements from a single experiment and are representative of 3 
independent experiments.
RNase protection assay. RNA was extracted from microdissected parathyroid 
glands (pool of 5), and equal amounts of RNA were analyzed by 32P UTP– 
labeled reverse RNA probes. The intact probes before and after RNase treat-
ment and hybridization with tRNA used as a nonspecific control were 
included in each experiment. The templates for the antisense RNA probes 
were generated by PCR using a forward primer with an upstream T3 promot-
er sequence. The primers for the PTH pre-mRNA first intron sequence were 
as follows: 5′-ATTAACCCTCACTAAAGGGTTTCCAAGCATTCACCAT-
CA-3′ and 5′-CCTTTGAAACTCTCCCAACG-3′. For the GAPDH mRNA, 
sequences were as follows: 3′ UTR: 5′-GTGGACCTCATGGCCTACAT-3′ 
and 5′-ATTAACCCTCACTAAAGTGTGAGGGAGATGCT-3′. The antisense 
probe for the PTH mRNA 3′ UTR was transcribed from a linearized plasmid 
containing the rat PTH 3′ UTR using T7 RNA polymerase (10).
RNA transcription and labeling. Uniformly [α-32P]UTP–labeled transcripts 
were prepared as previously described (11). A transcript for the full-length 
mRNA was transcribed from either the full-length human PTH cDNA or the 
full-length rat PTH cDNA (11). Transcripts for the truncated human PTH 
mRNA without the 3′ UTR or the rat PTH mRNA with an internal deletion of 
the ARE (~90 nt) were also used (11). The resulting templates of the rat PTH 
cDNAs contained a stretch of approximately 150 bp of dT at the 3′ end.
IVDAs. Radiolabeled polyadenylated transcripts (200,000 counts/min) 
were incubated with 40 μg protein extracts. At timed intervals, samples 
were removed; RNA was extracted, separated on agarose gels, and analyzed 
by autoradiography as previously described (11).
Cell cultures and transient transfection. HEK293 cells were transiently trans-
fected in 24-well plates for RNA analysis and in 10-cm plates for protein 
extractions, with the indicated plasmids using a Ca phosphate transfection 
kit (Sigma-Aldrich). siRNA oligonucleotides were transiently cotransfected 
with expression plasmids, using Lipofectamine 2000 Reagent (Invitrogen). 
Total amount of DNA in cotransfection experiments was maintained con-
stant using an empty vector, as indicated. In some experiments, juglone 
(3–7 μM) or vehicle (ethanol) were added 48 hours after transfection for 
an additional 4 hours.
Figure 9
Model for the regulation of PTH mRNA stability by PTH mRNA 3′ 
UTR ARE binding proteins. Under basal conditions, there is a bal-
anced interaction of the PTH mRNA with its stabilizing proteins AUF1 
(isoforms p37, p40, p42 and p45) and Unr and the destabilizing protein 
KSRP. In hypocalcemia or CKD, Pin1 is inactive, resulting in KSRP 
phosphorylation and hence its inactivation. This would allow AUF1 and 
Unr to bind the PTH mRNA 3′ UTR ARE with a greater affinity, leading 
to increased PTH mRNA stability.
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Northern blots and immunoblots. RNA was extracted using peqGOLD Tri-
Fast (PeqLab Biotechnologie) and analyzed as previously described (11). 
For immunoblots, proteins were analyzed by SDS-PAGE as previously 
described (11).
Protein extractions. For IVDAs, postmitochondrial extracts were prepared 
from cultured cells as before (11). Parathyroid extracts were prepared simi-
larly from a pool of 5 rats in each group. For Western blots and RIP, cultured 
cells or parathyroid glands (pool of 5 rats) were prepared using RIPA buffer 
containing 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 
and protease inhibitors (11). Extracts were stored in aliquots at –80°C.
Antibodies. Anti-KSRP was a generous gift from R. Gherzi (Istituto Nazio-
nale per la Ricerca sul Cancro, Genova, Italy). The anti-FLAG, anti–α-tubu-
lin, and anti-phosphoserine were from Sigma-Aldrich. Anti-GAPDH and 
anti-Pin1 were from Santa Cruz Biotechnology Inc. Anti-PTH monoclonal 
antibody used for immunohistochemistry was from AbD Serotec.
Plasmids. The human PTH gene, including exons and introns, was in 
pcDNA3 (11). FLAG-KSRP in pcDNA3 contained FLAG-tagged full-length 
KSRP, KSRP S193A, or T692A and was kindly provided by R. Gherzi. The 
GH expression plasmid was kindly provided by O. Meyuhas (Hebrew Uni-
versity–Hadassah Medical School, Jerusalem, Israel). The GH–PTH mRNA 
63-nt plasmid was previously described (5) and contained the 63-nt rat 
PTH mRNA ARE cloned between the 3′ of the GH mRNA coding sequence 
and the GH mRNA 3′ UTR. Empty control vector pcDNA3 (Invitrogen) 
was used as indicated. GFP-Pin1, Pin1 K63A, and Pin1 W34A expression 
plasmids were kindly provided by K.P. Lu (Department of Medicine, Beth 
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 
USA) (38) and Pin1 R68/69A by S. Ferrari (Institute of Molecular Cancer 
Research, University of Zürich, Zürich, Switzerland) (34).
siRNAs. siRNAs targeting the control CAT sequence were as follows: 5′-
r(GACGGUGAGCUGGUGAUAU)d(TT)-3′, KSRP: 5′-AAGATCAACCG-
GAGAGCAAGA-3′ and Pin1: r(CCGCCAGAUUCUCCCUUAA)d(TT). All 
were from QIAGEN.
PCR primers for qRT-PCR. Rat PTH primers were as follows: 5′-
TTGTCTCCTTACCCAGGCAGAT-3′ and 5′-TTTGCCCAGGTTGTG-
CATAA-3′. Primers for human PTH were as follows: 5′-GGGTCTGCAGTC-
CAATTCAT-3′ and 5′-CAGATTTCCCATCCGATTTT-3′. Primers for rat 
HPRT were as follows: 5′-TTGGATACAGGCCAGACTTTGTT-3′ and 
5′-AAGTGCTCATTATAGTCAAGGGCAT-3′. Primers for human HPRT 
were as follows: 5′-TTTGAATCATGTTTGTGTCATTAGTGA-3′ and 5′ 
TTCCAAACTCAACTTGAACTCTCATC-3′.
RIP. RIP was performed as previously described (11). In brief, thyropara-
thyroid glands (pool of 6) were roughly chopped and cross-linked. Equal 
amounts of whole-cell extracts were immunoprecipitated with anti-KSRP 
or IgG as control. RNA was extracted, and equal amounts were reverse 
transcribed with High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) and analyzed by qPCR and SYBR Green ROX Mix (ABgene). In 
some experiments, qPCR end products were run on agarose gels.
Site-directed mutagenesis. QuikChange site-directed mutagenesis kit (Strat-
agene) was used according to the manufacturer’s instructions. The primers 
for KSRP S181A mutagenesis were as follows: 5′-GGCTGCAAAGTACA-
GATTGCTCCAGACAGCGGTGGCCTACC-3′ and 5′-GGTAGGCCACC-
GCTGTCTGGAGCAATCTGTACTTTGCAGCC-3′.
Nuclear run-on assays. Nuclear run-ons were performed as previously 
described (2). In brief, nuclei were extracted from parathyroid glands (pool 
of 5–7). The nuclei were incubated in reaction buffer containing [α-32P] UTP 
for 15 minutes at 37°C. RNA was extracted using peqGOLD TriFast, and 
equal amounts of radioactive RNA were hybridized to a nitrocellulose mem-
brane containing linearized and denatured cDNAs for the indicated genes.
Immunohistochemistry and in situ hybridization. Immunohistochemistry was 
performed as previously described (24). Slides were analyzed using anti-
PTH antibodies and anti-Pin1 antibodies or IgG as control. In situ hybrid-
ization was performed as previously described (39). For quantification, 
slides were analyzed by the Ariol SL-50 system (Applied Imaging).
In gel proteolysis and mass spectrometry analysis. The immunoprecipitated pro-
teins were run on an SDS-PAGE, stained, and the proteins from the excised 
gel slices reduced (10 mM DTT), modified with 40 mM iodoacetamide, and 
trypsinized (modified trypsin; Promega) at a 1:100 enzyme-to-substrate ratio. 
The resulting tryptic peptides were resolved by reverse-phase chromatogra-
phy on 0.075 × 200–mm fused silica capillaries packed with Reprosil reversed 
phase material (Dr. Maisch GmbH). The peptides were eluted with linear 
65-minute gradients of 5% to 45% and 15 minutes at 95% acetonitrile with 
0.1% formic acid in water at flow rates of 0.25 μl/min. Mass spectrometry was 
performed by an ion-trap mass spectrometer (Orbitrap; Thermo Scientific) in 
a positive mode using repetitively full MS scan followed by collision-induced 
dissociation (CID) of the 7 most dominant ions selected from the first MS 
scan. The analysis was done with and without multistage activation. The 
mass spectrometry data were analyzed using Sequest 3.31 software (J. Eng and 
J. Yates, University of Washington, Seattle, Washington, USA; and Thermo 
Finnigan) searching against the vertebrate part of the NR-NCBI database.
Statistics. Values are reported as mean ± SEM unless stated otherwise. A 
2-tailed P value was considered significant when less than 0.05.
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